SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Prelude Therapeutics Reports Q3 Net Loss of $12.5 Million

Prelude reported a Q3 net loss of $12.5 million, or $0.12 per share, compared with $19.7 million, or $0.26 per share, a year earlier. It had $142.7 million in cash, equivalents, restricted cash and marketable securities at September 30, 2026, and expects funding into Q2 2028.

PRLD

Prelude reported a Q3 net loss of $12.5M, or $0.12 per share, versus $19.7M, or $0.26 per share, a year earlier. It had $142.7M in cash, equivalents, restricted cash and marketable securities at September 30, 2026, and expects funding into Q2 2028.Material DetailsContext by AI AnalystThis update pl…

Related stories